Evidence map›Paper›PMID 36975453›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study.

Wei Zhang, Daphne P Guh, Tima Mohammadi, Reka E Pataky, Alexander C T Tam, Larry D Lynd, Annalijn I Conklin

Open access · goldFull text read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Head and Neck Cancers Medical Costs in a Universal Health System: A Population-Based Case-Control Study.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wei ZhangCentre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
Daphne P GuhCentre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
Tima MohammadiCentre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
Reka E PatakyCanadian Centre for Applied Research in Cancer Control, BC Cancer, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0003-0159-582X
Alexander C T TamCentre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
Larry D LyndCentre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
Annalijn I ConklinCentre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.ORCID 0000-0002-6532-8790
University of British Columbia · CASt. Paul's Hospital · CACanadian Centre for Applied Research in Cancer Control · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year in British Columbia (BC), Canada. Using linked administrative health data, we followed a cohort of men aged ≥ 50 years at diagnosis with PCa between 2010 and 2017 (Cohort 1) from the diagnosis date until the date of death, the last date of observation, or 31 December 2019. Patients who died from PCa after 1 January 2010, were selected for Cohort 2. PCa attributable costs were estimated by comparing costs in patients to matched controls. Cohort 1 (

Indexed as

Prostatic NeoplasmsAgedAndrogen AntagonistsBritish ColumbiaCohort StudiesHealth Care CostsHumansMaleAndrogen Antagonistsadministrative datacost evaluationhealthcare costsprostate cancer

Identifiers

PMID36975453
PMCPMC10047657
OpenAlexW4323565215

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read2
measurements read22
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.